Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Merck's Cancer Vaccine Hits Big | Raleigh News
Merck’s personalized cancer vaccine Intismeran delivered a blockbuster result in a major melanoma trial, outperforming Keytruda alone and sparking a 43 billion dollar surge in Merck’s stock. Designed to target each patient’s unique tumor mutations, the vaccine could become a key revenue pillar as Keytruda’s patent expires in 2028, leaving Merck vulnerable to generic competition. The success validates mRNA cancer vaccine tech and opens doors for trials in kidney, bladder, and lung cancers—potential game-changers that could secure Merck’s future beyond its flagship drug’s expiration. Listen in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.